.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,759,394

« Back to Dashboard

Claims for Patent: 7,759,394

Title:Diclofenac formulations and methods of use
Abstract:Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
Inventor(s): Reiner; Giorgio (Como, IT), Reiner; Alberto (Como, IT), Meyer; Andreas (Neuenburg, DE)
Assignee: APR Applied Pharma Research SA (Balerna, CH)
Application Number:11/455,120
Patent Claims: 1. A method of treating migraine associated with phonophobia and photophobia in a human patient within two hours of administration comprising: a) providing a liquid formulation comprising about 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof in combination with an alkali metal carbonate or bicarbonate, wherein said formulation: i) is provided as a powder formulation and dissolved or suspended in water immediately before administration, or as a liquid formulation that is ingested with or without further mixing; ii) optionally has been found to achieve a maximum plasma concentration (C.sub.max) (arithmetic mean) of from about 1500 to about 2500 ng/ml; and iii) has been found to achieve a time to maximum plasma concentration (t.sub.max) (arithmetic mean) in from about 10 to about 25 minutes; b) orally administering said formulation to a patient suffering from migraine associated with photophobia and phonophobia, and c) thereby relieving said photophobia and said phonophobia in said patient within two hours of administration.

2. The method of claim 1 wherein said patient is suffering from migraine that requires sustained migraine relief for at least 24 hours.

3. The method of claim 1 wherein said liquid formulation comprises about 50 mg. of diclofenac potassium.

4. The method of claim 1 wherein said formulation has been found to achieve t.sub.max in from about 10 to about 20 minutes.

5. The method of claim 1 wherein said formulation is provided as a powder formulation, further comprising dissolving or suspending said powder in water immediately before administration.

6. A method of treating recurrent migraine requiring 24 hour treatment in a human patient suffering from migraine comprising: a) providing a liquid formulation comprising about 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof in combination with an alkali metal carbonate or bicarbonate, wherein said formulation: i) is provided as a powder formulation and dissolved or suspended in water immediately before administration, or as a liquid formulation that is ingested with or without further mixing; ii) optionally has been found to achieve a maximum plasma concentration (C.sub.max) (arithmetic mean)of from about 1500 to about 2500 ng/ml; and iii) has been found to achieve time to maximum plasma concentration (t.sub.max) (arithmetic mean) in from about 10 to about 25 minutes; b) orally administering said formulation to said patient; and c) thereby providing sustained migraine relief to said patient for at least 24 hours.

7. The method of claim 6 wherein said patient suffers from headache pain and either photophobia or phonophobia or both.

8. The method of claim 6 wherein said liquid formulation comprises about 50 mg. of diclofenac potassium.

9. The method of claim 6 wherein said C.sub.max has been found to have an inter-subject variability of less than about 70%.

10. The method of claim 6 wherein said t.sub.max has been found to have an inter-subject variability of less than about 70%.

11. The method of claim 6 wherein said formulation has been found to achieve t.sub.max in from about 10 to about 20 minutes.

12. The method of claim 6 wherein said formulation is provided as a powder formulation, further comprising dissolving or suspending said powder in water immediately before administration.

13. A method of treating migraine in a human patient, including headache pain, nausea, photophobia and phonophobia, within two hours after administration, comprising: a) providing a liquid formulation comprising about 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof in combination with an alkali metal carbonate or bicarbonate, wherein said formulation: i) is provided as a powder formulation and dissolved or suspended in water immediately before administration, or as a liquid formulation that is ingested with or without further mixing; ii) optionally has been found to achieve a maximum plasma concentration (C.sub.max) (arithmetic mean) of from about 1500 to about 2500 ng/ml; and iii) has been found to achieve time to maximum plasma concentration (t.sub.max) (arithmetic mean) in from about 10 to about 20 minutes; b) orally administering said formulation to a patient suffering from migraine, including headache pain, nausea, photophobia and phonophobia; and c) thereby treating said migraine, headache pain, nausea, photophobia and phonophobia in said patient within two hours of administration, wherein said migraine is defined as a disease manifested in a population of patients by periodic attacks of headache pain, nausea, photophobia and phonophobia.

14. The method of claim 13 wherein said patient suffers from headache pain and either photophobia or phonophobia or both.

15. The method of claim 13 wherein said C.sub.max has been found to have an inter-subject variability of less than about 70%.

16. The method of claim 13 wherein said t.sub.max has been found to have an inter-subject variability of less than about 70%.

17. The method of claim 13 wherein said liquid formulation comprises about 50 mg. of diclofenac potassium.

18. The method of claim 13 wherein said formulation has been found to achieve t.sub.max in from about 10 to about 20 minutes.

19. The method of claim 16 wherein said formulation is provided as a powder formulation, further comprising dissolving or suspending said powder in water immediately before administration.

20. A method of treating headache pain, nausea, phonophobia and photophobia in a human patient within two hours of administration comprising: a) providing a pharmaceutical formulation comprising about 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof in combination with an alkali metal carbonate or bicarbonate, wherein said formulation: i) has been found to achieve an average maximum plasma concentration (C.sub.max) (arithmetic mean) of from about 1400 to about 2500 ng/ml; and ii) has been found to achieve an average time to maximum plasma concentration t.sub.max (arithmetic mean) in from about 10 to about 35 minutes; and b) orally administering said formulation to a patient suffering from photophobia and Phonophobia; thereby treating said headache pain, nausea, photophobia and phonophobia within two hours of administration.

21. The method of claim 20 wherein said formulation has been found to reach a C.sub.max of greater than 1500 ng/ml, and a t.sub.max of less than 30 minutes, and further wherein said C.sub.max has been found to reach an average C.sub.max when tested in a fasted state, and said t.sub.max has been found to reach an average t.sub.max when tested in a fasted state.

22. A method of treating recurrent migraine requiring 24 hour treatment in a human patient suffering from migraine, and providing relief from said migraine for at least 24 hours without rebound, comprising: a) providing a pharmaceutical formulation comprising about 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof in combination with an alkali metal carbonate or bicarbonate, wherein said formulation: i) has been found to achieve an average maximum plasma concentration (C.sub.max) (arithmetic mean) of from about 1400 to about 2500 ng/ml; and ii) has been found to achieve an average time to maximum plasma concentration t.sub.max (arithmetic mean) in from about 10 to about 35 minutes; and b) orally administering said formulation to said patient; thereby treating said recurrent migraine and providing relief from said migraine for at least 24 hours without rebound.

23. The method of claim 22 wherein said formulation has been found to reach a C.sub.max of greater than 1500 ng/ml, and a t.sub.max of less than 30 minutes, and further wherein said C.sub.max has been found to reach an average C.sub.max when tested in a fasted state, and said t.sub.max has been found to reach an average t.sub.max when tested in a fasted state.

24. A method of treating headache pain, nausea, phonophobia and photophobia in a human patient within two hours of administration comprising: a) providing a pharmaceutical formulation comprising about 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof in combination with an alkali metal carbonate or bicarbonate, wherein greater than 90% of said diclofenac dissolves completely in 50 ml. of water at 25.degree. C. under continuous stirring for fifteen minutes at pH 6.8; and b) orally administering said formulation to a patient suffering from photophobia and phonophobia, and thereby relieving said photophobia and phonophobia within two hours of administration.

25. A method of treating recurrent migraine requiring 24 hour treatment in a human patient suffering from migraine comprising: a) providing a pharmaceutical formulation comprising about 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof in combination with an alkali metal carbonate or bicarbonate, wherein greater than 90% of said diclofenac dissolves completely in 50 ml. of water at 25.degree. C. under continuous stirring for fifteen minutes at pH 6.8; b) orally administering said formulation to said patient; thereby treating said recurrent migraine for at least twenty four hours after administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc